Bone mineral density in prepubertal asthmatics receiving corticosteroid treatment

M. Harris, S. Hauser, T. V. Nguyen, P. J. Kelly, C. Rodda, J. Morton, N. Freezer, B. J.G. Strauss, J. A. Eisman, J. L. Walker

Research output: Contribution to journalArticleResearchpeer-review

40 Citations (Scopus)

Abstract

Objective: To examine whether bone mass is reduced in prepubertal, asthmatics receiving high doses of inhaled corticosteroids. Methodology: A cross-sectional comparison of lumbar spine-bone mineral density (LS-BMD) was undertaken in 76 subjects after stratifying them according to dosage and administration route of corticosteroid. Results: Weight was the only independent predictor of LS-BMD (r2 = 0.38). Children receiving greater than 800 μg/day of inhaled corticosteroid plus intermittent oral corticosteroid had a significantly lower weight-adjusted LS-BMD than children treated with 400-800 μg/day of inhaled corticosteroid (mean difference: 0.06 g/cm2, 95% confidence interval (CI): -0.02 to -0.10). A significant difference in weight-adjusted LS-BMD persisted when all children receiving greater than 800 μg/day of inhaled corticosteroid, irrespective of additional oral corticosteroid treatment, were compared with children receiving 400-800 μg/day of inhaled corticosteroid (mean difference: - 0.05 g/cm2, 95%CI interval: -0.02 to -0.09). Bone mass was similar in children not receiving any inhaled corticosteroid and those treated with 400-800 μg/day of inhaled corticosteroid. Conclusions: A reduced bone mass in prepubertal asthmatic children receiving high doses of inhaled corticosteroids may predetermine a compromised peak bone mass and increase osteoporotic fracture risk in adulthood.

Original languageEnglish
Pages (from-to)67-71
Number of pages5
JournalJournal of Paediatrics and Child Health
Volume37
Issue number1
DOIs
Publication statusPublished - 28 Feb 2001

Keywords

  • Asthma
  • Bone mineral density
  • Corticosteroids

Cite this